Literature DB >> 20881319

Adaptation to extreme stress: post-traumatic stress disorder, neuropeptide Y and metabolic syndrome.

Ann M Rasmusson1, Paula P Schnurr, Zofia Zukowska, Erica Scioli, Daniel E Forman.   

Abstract

The prevalence rates of obesity and metabolic syndrome are on the rise in the United States. Epidemiological surveys suggest that the rates of these medical conditions are especially high among persons with psychiatric disorders, including post-traumatic stress disorder (PTSD). A variety of factors are thought to contribute to the risk for metabolic syndrome, including excessive caloric intake, decreased activity and energy expenditure, use of certain medications, stress and genetic influences. Recent research demonstrates that stress, acting through the neuropeptide Y (NPY) and glucocorticoid systems, potentiates the development of obesity and other aspects of metabolic syndrome in mice fed a high caloric, fat and sugar diet. Alterations in the NPY and glucocorticoid systems also impact behavioral adaptation to stress, as indicated by studies in animals and persons exposed to severe, life-threatening or traumatic stress. The following review examines the biology of the NPY and neuroactive steroid systems as physiological links between metabolic syndrome and PTSD, a paradigmatic neuropsychiatric stress disorder. Hopefully, understanding the function of these systems from both a translational and systems biology point of view in relation to stress will enable development of more effective methods for preventing and treating the negative physical and mental health consequences of stress.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20881319     DOI: 10.1258/ebm.2010.009334

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  39 in total

Review 1.  Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy.

Authors:  Richard L Hauger; J Alberto Olivares-Reyes; Frank M Dautzenberg; James B Lohr; Sandra Braun; Robert H Oakley
Journal:  Neuropharmacology       Date:  2011-11-25       Impact factor: 5.250

Review 2.  NPY and stress 30 years later: the peripheral view.

Authors:  Dalay Hirsch; Zofia Zukowska
Journal:  Cell Mol Neurobiol       Date:  2012-01-24       Impact factor: 5.046

3.  The retinoid-related orphan receptor alpha (RORA) gene and fear-related psychopathology.

Authors:  Mark W Miller; Erika J Wolf; Mark W Logue; Clinton T Baldwin
Journal:  J Affect Disord       Date:  2013-08-17       Impact factor: 4.839

4.  Effect of recurrent yohimbine on immediate and post-hoc behaviors, stress hormones, and energy homeostatic parameters.

Authors:  D P Figlewicz; S R Hill; J L Jay; C H West; A S Zavosh; A J Sipols
Journal:  Physiol Behav       Date:  2014-02-22

Review 5.  Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder.

Authors:  Graziano Pinna; Ann M Rasmusson
Journal:  J Neuroendocrinol       Date:  2012-01       Impact factor: 3.627

Review 6.  Molecular and Cellular Effects of Traumatic Stress: Implications for PTSD.

Authors:  Matthew J Girgenti; Brendan D Hare; Sriparna Ghosal; Ronald S Duman
Journal:  Curr Psychiatry Rep       Date:  2017-09-25       Impact factor: 5.285

7.  Neurobehavioral assessment in forensic practice.

Authors:  George W Woods; David Freedman; Stephen Greenspan
Journal:  Int J Law Psychiatry       Date:  2012-10-09

8.  Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk.

Authors:  Satish A Eraly; Caroline M Nievergelt; Adam X Maihofer; Donald A Barkauskas; Nilima Biswas; Agorastos Agorastos; Daniel T O'Connor; Dewleen G Baker
Journal:  JAMA Psychiatry       Date:  2014-04       Impact factor: 21.596

9.  Treatment-related reductions in PTSD and changes in physical health symptoms in women.

Authors:  Jillian C Shipherd; Gretchen Clum; Michael Suvak; Patricia A Resick
Journal:  J Behav Med       Date:  2013-03-08

10.  NPY Y1 receptors differentially modulate GABAA and NMDA receptors via divergent signal-transduction pathways to reduce excitability of amygdala neurons.

Authors:  Andrei I Molosh; Tammy J Sajdyk; William A Truitt; Weiguo Zhu; Gerry S Oxford; Anantha Shekhar
Journal:  Neuropsychopharmacology       Date:  2013-01-28       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.